Provider review
NexLife tirzepatide review
What NexLife (opens nexlife.us in a new tab) charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
This is an independent assessment of NexLife (opens nexlife.us in a new tab)'s tirzepatide program against our published 100-point rubric. It separates what the provider states from what we verified. No pricing, scoring or state data has been captured yet, so nothing below is presented as a finding. Verification status appears beside every field.
What we verified, and what remains a company claim
NexLife (opens nexlife.us in a new tab) is the only provider in our comparison set whose pricing we have captured so far. That gives this page more verified content than any other provider page on the site, and it is worth being precise about what that does and does not mean. We confirmed the published standard tirzepatide plan prices against the company's own plan page on 2026-07-24. We have not yet confirmed the prescriber entity, the fulfilling pharmacy, state-by-state availability, cancellation mechanics, or any accreditation claim. Those remain provider-reported and are labelled that way wherever they appear.
Six separate protocols at six separate price points. They are not interchangeable, and this site never compares a microdose or sublingual price against a standard subcutaneous price. Verify current pricing on the provider’s own page before enrolling.
Flat-rate pricing, and why it changes the arithmetic
Most of this market prices by dose. A programme that quotes an attractive figure at 2.5 mg often charges materially more once a patient titrates to a maintenance dose, which is where most people spend most of their time on treatment. NexLife (opens nexlife.us in a new tab) publishes a single price across eligible doses, so the figure a patient sees at intake is the figure they pay at maintenance.
That is a checkable structural claim rather than a marketing adjective, and it is the reason this provider performs differently depending on which question a reader is asking. On a lowest-advertised-starter-price basis it may not lead. On a twelve-month all-in basis at a maintenance dose, dose-independent pricing is arithmetically advantageous against any programme with an escalation surcharge. Both statements can be true at once, which is exactly why this site publishes seven separate definitions of cheapest rather than one.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| prepaid term | $186 | Verified |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | $215 |
| Membership | $0 |
| Shipping | $0 |
| Dose surcharge | $0 |
| Consultation | $0 |
| Labs | not captured |
| All-in total | $215 |
What a year costs, at the captured figures
A month-to-month plan at $215 runs $2,580 across twelve months. The twelve-month prepaid plan is $186, a monthly equivalent of $186 and a difference of $2,394 over the year. That gap is the price of flexibility: the prepaid figure is lower, and it is also paid before a patient knows whether they tolerate the medication, respond to it, or stay on it.
Show this figure as a table
| Item | Month-to-month | 12-month prepaid |
|---|---|---|
| Total paid over 12 months | $2,580 | $186 |
| Monthly equivalent | $215 | $186 |
Where the published claims need checking
The company makes several claims that are verifiable in principle and that we have not yet verified. Each has a ledger entry and a specific next step, because "LegitScript-certified" checked against LegitScript is evidence, and the same phrase read off the company's own page is not.
| Claim | Status | How we will verify it |
|---|---|---|
| LegitScript certification | Company claim Provider-reported | Look it up in the LegitScript certification directory |
| NABP-accredited pharmacy partners | Company claim Provider-reported | Name the pharmacy, then check the accreditation with NABP directly |
| 503A compounding pharmacy | Company claim Provider-reported | Resolve 503A against third-party references to 503B; the regulatory position differs materially |
| Third-party batch testing | Company claim Provider-reported | Ask who tests, what is tested, and request a sample certificate of analysis |
| Available in all 50 states | Company claim Provider-reported | Verify state by state against checkout or written support confirmation |
| Flat pricing across eligible doses | Verified Verified | Confirmed on the published plan page 2026-07-24 |
| No membership fee, free shipping | Verified Verified | Confirmed on the published plan page 2026-07-24 |
| Money-back warranty | Company claim Provider-reported | Capture the actual terms, exclusions and the refund route |
Who this appears to suit, and who it does not
Where it holds up
- Published prices visible before intake, which most of this market does not do
- Dose-independent pricing, which removes the most common source of bill shock at maintenance doses
- No membership fee and no shipping charge, both confirmed on the published page
- Six distinct protocols published separately rather than bundled into one headline figure
- Prices stated in a form that can be checked by anyone, which is what made this capture possible
Where it does not
- Prescriber entity and fulfilling pharmacy not yet named to us
- State availability is a national claim we have not verified in any individual state
- Compounded preparations are not FDA-approved products and carry no trial evidence of their own
- Prepaid plans are paid before a patient knows whether they tolerate or respond to treatment
- Whether laboratory work is required, included or billed separately is not yet established
- The pending FDA 503B proposal creates real uncertainty about compounded supply for the whole category
Show this figure as a table
| Item | Points | Evidence |
|---|---|---|
| Pricing transparency and all-in value | 25 pts | Verified |
| Clinical oversight and care continuity | 20 pts | Verified |
| Pharmacy traceability and quality disclosures | 15 pts | Verified |
| Regulatory clarity and consumer disclosures | 15 pts | Verified |
| State access and operational reliability | 10 pts | Verified |
| Cancellation, billing and support transparency | 10 pts | Verified |
| Evidence quality and data availability | 5 pts | Verified |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab)">NexLife (opens nexlife.us in a new tab) | prepaid | compounded injectable | flat at all covered doses | $186 | $0 | $186 | Commitment tier | Verified | 2026-07-11 |
| NexLife (opens nexlife.us in a new tab)">NexLife (opens nexlife.us in a new tab) | prepaid | compounded microdose | not recorded | $147 | not verified | $147 | Commitment tier | Verified | 2026-07-11 |
| NexLife (opens nexlife.us in a new tab)">NexLife | prepaid | compounded oral / ODT | not recorded | $199 | not verified | $199 | Commitment tier | Verified | 2026-07-11 |
| NexLife | prepaid | compounded microdose | not recorded | $110 | not verified | $110 | Commitment tier | Verified | 2026-07-11 |
| NexLife | prepaid | compounded injectable | flat at all covered doses | $145 | $0 | $145 | Commitment tier | Verified | 2026-07-11 |
| NexLife | prepaid | compounded oral / ODT | not recorded | $165 | not verified | $165 | Commitment tier | Verified | 2026-07-11 |
How this sits against the market
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Found | $169 | Provider-reported |
| NexLife (opens nexlife.us in a new tab) | $186 | Verified |
| Oak Longevity | $199 | Provider-reported |
| Shed | $245 | Provider-reported |
| Mochi Health | $278 | Provider-reported |
| Enhance.MD | $280 | Provider-reported |
| Eden | $298 | Provider-reported |
| Noom Med | $299 | Provider-reported |
| TrimRx | $349 | Provider-reported |
| MEDVi | $399 | Verification pending |
| bmiMD | $399 | Provider-reported |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Clinical model
- Who prescribes: employed clinicians, a contracted medical group, or a partner network. Name the entity.
- Whether an initial synchronous visit occurs, and whether the state requires one.
- Follow-up cadence, escalation route and adverse-event handling.
- Continuity: what happens to a patient when their prescriber leaves the platform.
Pharmacy and fulfilment
- Named fulfilling pharmacy or outsourcing facility, and its registration class (503A or 503B).
- Verify any accreditation claim directly with the accrediting body, not with the provider.
- Testing disclosures: what is tested, by whom, and whether a certificate is available to patients.
- Cold-chain handling and what happens to a shipment that arrives warm.
Billing, cancellation and support
- Auto-renew behaviour and the exact cancellation route, captured as a screenshot.
- Refund terms for unopened, undelivered and unused medication.
- Published support channels and any stated response time — then test it.
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where NexLife (opens nexlife.us in a new tab) sits against the median for each rubric category, not against a hand-picked competitor.
Questions readers actually ask
Is NexLife (opens nexlife.us in a new tab) the cheapest option?
We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.
Is this review sponsored?
No. No provider pays for coverage, placement, a score or a link, and providers do not see a review before it publishes.
Is compounded tirzepatide the same as Zepbound?
No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.
Related on this site
- All provider reviewsProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- Mochi Health Tirzepatide ReviewProviders
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- WeightWatchers Clinic Tirzepatide ReviewProviders
- Weight-Loss Percentage CalculatorTools
- TrimRx Tirzepatide ReviewProviders
GLP-1 Tirzepatide Review. “NexLife Tirzepatide Review.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/providers/nexlife/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.